DelveInsight’s, “Postmenopausal Osteoporosis Pipeline Insight 2023” report provides comprehensive insights about 18+ companies and 18+ pipeline drugs in the Postmenopausal Osteoporosis pipeline landscape. It covers the Post-Menopausal Osteoporosis pipeline drug profiles, including Post-Menopausal Osteoporosis clinical trials and nonclinical stage products. It also covers the Post-Menopausal Osteoporosis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
For Post-Menopausal Osteoporosis Emerging drugs, the Post-Menopausal Osteoporosis pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The Post-Menopausal Osteoporosis pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.
In the Post-Menopausal Osteoporosis Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, Post-Menopausal Osteoporosis clinical trials studies, Post-Menopausal Osteoporosis NDA approvals (if any), and product development activities comprising the technology, Post-Menopausal Osteoporosis collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
Key takeaways from the Post-Menopausal Osteoporosis Pipeline Insight Report
Request a sample and discover the recent breakthroughs happening in the Post-Menopausal Osteoporosis Pipeline landscape @ Post-Menopausal Osteoporosis Pipeline Outlook Report
Post-Menopausal Osteoporosis Overview
Osteoporosis is a metabolic bone disorder that is characterized by low bone mass and micro-architectural deterioration of bone tissue. Fractures of the proximal femur, the vertebrae and the distal radius are the most frequent osteoporotic fractures, although most fractures in the elderly are probably at least partly related to bone fragility. The incidence of fractures varies greatly by country, but on average up to 50% of women >50 years of age are at risk of fractures. Fractures severely affect the quality of life of an individual and are becoming a major public health problem owing to the ageing population.
Post-Menopausal Osteoporosis Emerging Drugs Profile
TVB-009 is a Denosumab biosimilar being developed by Teva Pharmaceutical for the treatment of patients with Postmenopausal osteoporosis. TVB-009 is a RANK ligand inhibitor and is currently in Phase III stage of clinical trial evaluation to treat Postmenopausal osteoporosis.
SB16 is a Denosumab biosimilar being developed by Samsung Bioepis to treat Postmenopausal osteoporosis. The company is conducting a Phase III clinical trial to compare the efficacy and safety of SB16 with the original drug on 432 post-menopausal osteoporosis patients in six countries.
For further information, refer to the detailed Post-Menopausal Osteoporosis Drugs Launch, Post-Menopausal Osteoporosis Developmental Activities, and Post-Menopausal Osteoporosis News, click here for Post-Menopausal Osteoporosis Ongoing Clinical Trial Analysis
Post-Menopausal Osteoporosis Pipeline Therapeutics Assessment
There are approx. 18+ key companies which are developing the therapies for Postmenopausal Osteoporosis. The companies which have their Postmenopausal Osteoporosis drug candidates in the most advanced stage, i.e. phase III include, Teva Pharmaceutical.
Post-Menopausal Osteoporosis Pipeline: Phases
Find out more about the Post-Menopausal Osteoporosis Pipeline Segmentation, Therapeutics Assessment, and Post-Menopausal Osteoporosis Emerging Drugs @ Post-Menopausal Osteoporosis Treatment Landscape
Scope of the Post-Menopausal Osteoporosis Pipeline Report
Dive deep into rich insights for drugs for Post-Menopausal Osteoporosis Pipeline Companies and Therapies, click here @ Post-Menopausal Osteoporosis Unmet Needs and Analyst Views
Table of Content
Got Queries? Find out the related information on Post-Menopausal Osteoporosis Mergers and acquisitions, Post-Menopausal Osteoporosis Licensing Activities @ Post-Menopausal Osteoporosis Recent Trends, and Future Perspectives
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media ContactCompany Name: DelveInsightContact Person: Yash BhardwajEmail: Send EmailPhone: +91 9568243403Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/